Versant Venture Capital Vi, L.p. - Net Worth and Insider Trading
Versant Venture Capital Vi, L.p. Net Worth
The estimated net worth of Versant Venture Capital Vi, L.p. is at least $642 Million dollars as of 2024-06-06. Versant Venture Capital Vi, L.p. is the 10% Owner of IPSCO Tubulars Inc and owns about 13,630,909 shares of IPSCO Tubulars Inc (IPSC) stock worth over $421 Million. Versant Venture Capital Vi, L.p. is the 10% Owner of Akero Therapeutics Inc and owns about 3,092,698 shares of Akero Therapeutics Inc (AKRO) stock worth over $64 Million. Versant Venture Capital Vi, L.p. is also the 10% Owner of Oyster Point Pharma Inc and owns about 4,060,566 shares of Oyster Point Pharma Inc (OYST) stock worth over $45 Million. Besides these, Versant Venture Capital Vi, L.p. also holds Century Therapeutics Inc (IPSC) , Monte Rosa Therapeutics Inc (GLUE) , Black Diamond Therapeutics Inc (BDTX) , Passage Bio Inc (PASG) , Aligos Therapeutics Inc (ALGS) . Details can be seen in Versant Venture Capital Vi, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Versant Venture Capital Vi, L.p. has not made any transactions after 2022-08-09 and currently still holds the listed stock(s).
Transaction Summary of Versant Venture Capital Vi, L.p.
Versant Venture Capital Vi, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Versant Venture Capital Vi, L.p. owns 11 companies in total, including Aligos Therapeutics Inc (ALGS) , Black Diamond Therapeutics Inc (BDTX) , and Pandion Therapeutics Inc (PAND) among others .
Insider Ownership Summary of Versant Venture Capital Vi, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ALGS | Aligos Therapeutics Inc | 2020-10-20 | 10 percent owner |
| BDTX | Black Diamond Therapeutics Inc | 2020-11-30 | 10 percent owner |
| PAND | Pandion Therapeutics Inc | 2020-07-21 | 10 percent owner |
 | | 2020-12-15 | 10 percent owner |
| | 2020-03-03 | 10 percent owner |
| | 2020-01-21 | 10 percent owner |
| | 2021-10-18 | 10 percent owner |
| | 2022-04-29 | 10 percent owner |
| | 2021-06-24 | 10 percent owner |
| | 2021-06-28 | 10 percent owner |
| | 2022-08-09 | 10 percent owner |
Versant Venture Capital Vi, L.p. Latest Holdings Summary
Versant Venture Capital Vi, L.p. currently owns a total of 8 stocks. Among these stocks, Versant Venture Capital Vi, L.p. owns 13,630,909 shares of IPSCO Tubulars Inc (IPSC) as of June 22, 2021, with a value of $421 Million and a weighting of 65.6%. Versant Venture Capital Vi, L.p. owns 3,092,698 shares of Akero Therapeutics Inc (AKRO) as of January 21, 2020, with a value of $64 Million and a weighting of 10.02%. Versant Venture Capital Vi, L.p. also owns 4,060,566 shares of Oyster Point Pharma Inc (OYST) as of October 18, 2021, with a value of $45 Million and a weighting of 7.07%. The other 5 stocks Century Therapeutics Inc (IPSC) , Monte Rosa Therapeutics Inc (GLUE) , Black Diamond Therapeutics Inc (BDTX) , Passage Bio Inc (PASG) , Aligos Therapeutics Inc (ALGS) have a combined weighting of 17.31% among all his current holdings.
Latest Holdings of Versant Venture Capital Vi, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| IPSC | IPSCO Tubulars Inc | 2021-06-22 | 13,630,909 | 30.88 | 420,922,470 |
| AKRO | Akero Therapeutics Inc | 2020-01-21 | 3,092,698 | 20.79 | 64,297,191 |
| OYST | Oyster Point Pharma Inc | 2021-10-18 | 4,060,566 | 11.17 | 45,356,522 |
| IPSC | Century Therapeutics Inc | 2022-08-09 | 12,166,109 | 3.00 | 36,498,327 |
| GLUE | Monte Rosa Therapeutics Inc | 2021-06-28 | 8,897,053 | 4.09 | 36,388,947 |
| BDTX | Black Diamond Therapeutics Inc | 2020-11-30 | 6,449,348 | 4.65 | 29,989,468 |
| PASG | Passage Bio Inc | 2020-03-03 | 4,959,769 | 1.26 | 6,249,309 |
| ALGS | Aligos Therapeutics Inc | 2020-10-20 | 3,292,339 | 0.60 | 1,973,757 |
Holding Weightings of Versant Venture Capital Vi, L.p.
Versant Venture Capital Vi, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Versant Venture Capital Vi, L.p. has made a total of 1 transactions in IPSCO Tubulars Inc (IPSC) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in IPSCO Tubulars Inc is the acquisition of 100,000 shares on June 22, 2021, which cost Versant Venture Capital Vi, L.p. around $2 Million.
According to the SEC Form 4 filings, Versant Venture Capital Vi, L.p. has made a total of 11 transactions in Akero Therapeutics Inc (AKRO) over the past 5 years, including 1 buys and 10 sells. The most-recent trade in Akero Therapeutics Inc is the sale of 59,532 shares on January 21, 2020, which brought Versant Venture Capital Vi, L.p. around $1 Million.
According to the SEC Form 4 filings, Versant Venture Capital Vi, L.p. has made a total of 2 transactions in Oyster Point Pharma Inc (OYST) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Oyster Point Pharma Inc is the sale of 550,000 shares on October 18, 2021, which brought Versant Venture Capital Vi, L.p. around $8 Million.
More details on Versant Venture Capital Vi, L.p.'s insider transactions can be found in the Insider Trading History of Versant Venture Capital Vi, L.p. table.Insider Trading History of Versant Venture Capital Vi, L.p.
- 1
Versant Venture Capital Vi, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Versant Venture Capital Vi, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Versant Venture Capital Vi, L.p. is 47.49%. GuruFocus also compares Versant Venture Capital Vi, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Versant Venture Capital Vi, L.p. within 3 months outperforms 6 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Versant Venture Capital Vi, L.p.'s insider trading performs compared to the benchmark.
Performance of Versant Venture Capital Vi, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 6.51 | | | | | |
| Relative Return to S&P 500(%) | 9.04 | | | | | |
Versant Venture Capital Vi, L.p. Ownership Network
Versant Venture Capital Vi, L.p. Owned Company Details
What does Aligos Therapeutics Inc do?
Who are the key executives at Aligos Therapeutics Inc?
Versant Venture Capital Vi, L.p. is the 10 percent owner of Aligos Therapeutics Inc. Other key executives at Aligos Therapeutics Inc include 10 percent owner Roche Holding Ltd , 10 percent owner Roche Finance Ltd , and Chief Medical Officer Matthew W. Mcclure .
Aligos Therapeutics Inc (ALGS) Insider Trades Summary
Over the past 18 months, Versant Venture Capital Vi, L.p. made no insider transaction in Aligos Therapeutics Inc (ALGS). Other recent insider transactions involving Aligos Therapeutics Inc (ALGS) include a net purchase of 7,933,601 shares made by Carole Nuechterlein ,
In summary, during the past 3 months, insiders sold 0 shares of Aligos Therapeutics Inc (ALGS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aligos Therapeutics Inc (ALGS) were sold and 7,933,601 shares were bought by its insiders, resulting in a net purchase of 7,933,601 shares.
Aligos Therapeutics Inc (ALGS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aligos Therapeutics Inc Insider Transactions
Versant Venture Capital Vi, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Versant Venture Capital Vi, L.p.. You might contact Versant Venture Capital Vi, L.p. via mailing address: One Sansome Street, Suite 1650, San Francisco Ca 94104.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
